Posts filtered by tags: Cystic Fibrosis[x]


 

Cystic Fibrosis Patients Turn to Experimental Phage Therapy

Phages have not been approved by the Food and Drug Administration, but there is growing interest in the treatment for cystic fibrosis.
Tags: Antibiotics, Cystic Fibrosis, Infections, Drug Resistance (Microbial, Drugs (Pharmaceuticals, Bacteria, Lungs


Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a market force that could help tame climbing drug prices. But such tools only work when companies play fair.A lawsuit is now claiming that many top generic drug makers routinely conspired to avoid competition. In a more than filed in federal court in Connecticut, 44 states allege that 18 generic dr...
Tags: Deals, Startups, Lawsuit, Breast Cancer, Drugs, Cancer, Trends, Investing, Hypertension, Connecticut, Venture Capital, Private Equity, Fda, National, Biotech, Cystic Fibrosis


Vertex Continues Plan to Diversify, Strikes a $70M Pact With Kymera

Vertex Pharmaceuticals is best known for its cystic fibrosis franchise. But over the past several years Vertex has been making inroads elsewhere, and a deal it is announcing this morning continues that strategy.Vertex (NASDAQ: VRTX), of Boston, will pay privately held startup Kymera Therapeutics $70 million to form an alliance to develop a group of drugs for “serious specialty diseases.” Vertex won’t say which ones, but beyond cystic fibrosis (CF), where it has three FDA-approved drugs that gen...
Tags: Deals, Startups, Boston, Trends, Vc, Fda, GlaxoSmithKline, Biotech, Pain, Cystic Fibrosis, Life Sciences, CRISPR Therapeutics, Vertex, Merck KGaA, Hepatitis C, Vertex Pharmaceuticals


Your Sweat Will See You Now

A new device — wearable, wireless and battery free — improves the ability to monitor and diagnose health problems by analyzing the sweat on your skin.
Tags: News, Sensors, Diabetes, Exercise, Cystic Fibrosis, Skin, Sweating, Wearable Computing, Data-Mining and Database Marketing


New Mucus Study Could Hold the Key to Clearing Your Phlegm

Mucus, you fickle fiend—usually, you’re there keeping us safe from whatever nasties sneak inside of us. But then you turn, becoming a source of discomfort, canceled plans, and overall malaise. How I wish we knew you better.Read more...
Tags: Science, Cystic Fibrosis, Copd, Mucus, Phlegm


Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More

In the biotech investment and research communities this week, much of the attention was turned to Europe.Munich, Germany, hosted the annual conference of the European Society for Medical Oncology, where cancer drug developers unveiled the latest clinical data for experimental immunotherapies and drugs that treat the disease based on a tumor’s genetic signature. Also this week, the Clinical Trials on Alzheimer’s Disease conference took place in Barcelona, Spain. As with another Alzheimer’s meeti...
Tags: Startups, Drugs, Cancer, Trends, Investing, Alzheimer's Disease, Astrazeneca, Medicare, Fda, National, Pfizer, Abbvie, Biotech, Bain Capital, Stanford University, Cystic Fibrosis


Activist and YouTuber Claire Wineland dies at age 21

Inspirational speaker and YouTuber Claire Wineland, who had cystic fibrosis, died Sunday night. The 21-year-old activist had a successful lung transplant on August 26, but days later she suffered a severe stroke. According to BBC: In a post on its Facebook page, the Claire's Place Foundation said: "Our inspirational founder passed away. She was not in any pain and the medical staff said it was the most peaceful passing they had ever witnessed." At a 2017 TEDx talk, Ms Wineland spoke about ...
Tags: Video, News, Bbc, Cystic Fibrosis, Claire Wineland, Wineland, YouTuber Claire Wineland, Claire s Place Foundation


Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

Two imminent FDA rulings on two separate drugs aren’t just noteworthy for the patients they’ll help, but the long and winding road their developers have taken to get to this point.First is Alnylam Pharmaceuticals, which has spent 16 years and over $2 billion to try to bring an unproven form of medicine, RNA interference (RNAi), to market. A positive FDA decision, which could come by Saturday, would mark RNAi as a bona fide drug-making method, and Alnylam as its standard-bearer.Then there’s Amic...
Tags: Deals, Trends, Gout, Fda, National, Roundups, Cystic Fibrosis, Life Sciences, Clinical Trials, Medicare Advantage, Chris Collins, Samumed, Regeneron Pharmaceuticals, Gene Therapy, BioMarin Pharmaceutical, Alnylam


Moving Beyond Obesity, Vivus Strikes $135M Deal for Digestive Drug

Sales of weight loss drugs have been light, and the Vivus drug Qsymia is no exception. Facing declining revenue as well as a looming mountain of debt, Vivus has been casting about for a new strategy. It looks like it’s found one. Campbell, CA-based Vivus (NASDAQ: VVUS) has agreed to pay $135 million for the rights to sell a digestion drug, pancrelipase (Pancreaze), in the U.S. and Canada. The treatment is currently marketed by Janssen Pharmaceuticals. In a related deal, Vivus is raising c...
Tags: Deals, Startups, San Francisco, Trends, Canada, Food And Drug Administration, Fda, Biotech, Cystic Fibrosis, Life Sciences, Arena Pharmaceuticals, Eisai, Vivus, Janssen Pharmaceuticals, Orexigen Therapeutics, National blog main


Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More

The 2018 Winter Olympics will end soon, and we did not skate through these games without a performance-enhancing drug allegation rearing its ugly head. This time, the drug in question was meldonium (Mildronate), a product widely available over the counter in Russia and some Eastern European countries. Though Latvian pharmaceutical company Grindeks markets meldonium for heart conditions, the drug also reportedly boosts stamina and endurance. Meldonium is not approved by the FDA for any use...
Tags: Deals, Startups, Russia, Cancer, Trends, Investing, Merck, Food And Drug Administration, Affordable Care Act, Astrazeneca, Fda, National, Parkinson's Disease, Immunotherapy, Abbvie, Biotech


Watch this emotional moment when this woman takes her first breath after a double lung transplant

When she was nearly 30, Jennifer Jones learned that she had been misdiagnosed with allergies and asthma all her life. According to ABC 6 News, Jennifer discovered after the birth of her son, that she instead had Cystic Fibrosis, a disease that wreaks havoc (primarily) on the lungs. "Last year in October she went in and it was getting so bad they put her on oxygen full time," said Jennifer’s Fiancé, Rob Ronnenberg. Jennifer was put on a transplant list for new lungs in June, which is when ...
Tags: Post, Video, News, Abc, Rob, Cystic Fibrosis, Jennifer, Jennifer Jones, Lung Transplant, Rob Ronnenberg Jennifer


Doing Well Not Despite Being Sick, but BECAUSE of Being Ill.

B'SD 11 Av, 5777 I found this remarkable video online and want to share it with you. Do something upbeat with the inspiration you feel. Maybe I'll do a blogpost about YOU! Ready? Read the E-book or print edition of EMPOWER Yourself to Cope with a Medical Challenge .  _uacct = "UA-2042588-1"; urchinTracker(); Face Your Medical Problems with Dignity. Face Your Future with Optimism. Fill your life with wonder. [Au...
Tags: Health, Diabetes, Cystic Fibrosis, Terminal Illness, UA, Booklocker Publishing, Booklocker.com, Yocheved Golani, Claire Wineland, Medical Setbacks


Homology Med Bags $83.5M More, Fueling Push For Gene Editing Twist

One day after the release of a Nature Medicine paper warning of the potential hazards of testing CRISPR-Cas9 gene editing in humans, Homology Medicines, a startup advancing a different genetic surgery technique, has just grabbed a big round of funding to make its own clinical push. Homology, of Bedford, MA, wrapped up an $83.5 million Series B round this morning. A wide group of investors led by Deerfield Management provided the funding, bringing the company’s total amount raised to a who...
Tags: Deals, Startups, Boston, Dna, Trends, Vc, Novartis, Shire, Cystic Fibrosis, Temasek, Life Sciences, Editas Medicine, Clinical Trials, CRISPR Therapeutics, ARCH Venture Partners, David Scott


RNA Specialist Arcturus Therapeutics Gets $3M R&D Grant for CF Drug

San Diego-based Arcturus Therapeutics said today Cystic Fibrosis Foundation Therapeutics has agreed to provide $3 million to fund research and development of a new messenger RNA drug that could be broadly used to treat cystic fibrosis patients. The four-year-old startup has previously raised $37 million in research grants and other “non-dilutive” funding, and another $13 million from investors, according to Arcturus spokeswoman Neda Safarzadeh. Arcturus describes itself as “an RNA medicin...
Tags: Deals, Startups, Drugs, Entrepreneurship, Funding, Trends, Innovation, San Diego, Fda, Biotech, Financing, Cystic Fibrosis, Life Sciences, Vertex Pharmaceuticals, National blog main, National top stories


Medical News Today: Potential new treatment for cystic fibrosis uncovered

New research suggests that thymosin alpha 1 can correct the genetic defects typical of cystic fibrosis and stop the progression of the disease.
Tags: Cystic Fibrosis


The New Health Care: Why Cystic Fibrosis Patients in Canada Outlive Those in the U.S.

The most significant correlation seems to be insurance: Everyone in Canada has it.
Tags: News, Canada, Cystic Fibrosis, Health Insurance and Managed Care, Transplants


First Trial in Sight, Editas Cuts $90M Eye Drug Deal With Allergan

Slowly but surely, CRISPR-Cas9 gene editing treatments are working their way towards human clinical testing, spurring more large pharmaceutical companies to get in on their future. The latest today is Allergan, which has just aligned itself with Editas Medicine on treatments for a group of genetic eye diseases. Allergan (NYSE: AGN) will pay Cambridge, MA-based Editas (NASDAQ: EDIT) $90 million in cash up front to get an option to license up to five experimental gene editing treatments for...
Tags: Deals, Drugs, Boston, Trends, Novartis, Allergan, Berkeley, University Of California, Cystic Fibrosis, Life Sciences, Bayer, Editas Medicine, Clinical Trials, CRISPR Therapeutics, Gene Editing, Cambridge MA


Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More

We’ll start the roundup in Washington DC. The repeal of the Affordable Care Act, also known as Obamacare, began on the first day of the Trump administration. This week, the “replace” phase began with a Republican plan championed by House Speaker Paul Ryan (R-WI). President Trump backed it, too, but a lot of Republicans have come out against it for not being, well, enough of a replacement. (“Obamacare Lite” is one charge against it.) On the left, critics charge it will strip health coverag...
Tags: Google, Deals, Obamacare, Trends, People, Diabetes, Washington Dc, House, Affordable Care Act, Paul ryan, Fda, National, Novo Nordisk, Roundups, Cystic Fibrosis, Life Sciences


Vertex Bags Concert’s Rival CF Drug For $160M, Plans Combo Studies

Concert Pharmaceuticals has been plugging away with an experimental cystic fibrosis drug that, if successful, might someday pose a threat to Vertex Pharmaceuticals. So rather than wait to find out, Vertex today paid $160 million in cash, up front, to bring the drug in house. Boston-based Vertex (NASDAQ: [[tickerVRTX]]) has acquired CTP-656, a CF drug currently in Phase 2 testing, from Concert (NASDAQ: CNCE). Vertex could pay Concert, of Lexington, MA, another $90 million in downstream pay...
Tags: Deals, Drugs, Boston, Trends, Abbvie, Cystic Fibrosis, Life Sciences, Clinical Trials, CRISPR Therapeutics, Vertex, CTP, Hepatitis C, Kalydeco, Concert Pharmaceuticals, Moderna Therapeutics, Vertex Pharmaceuticals


Bio Roundup: Crazy ’16, Trials of ’17, Senate on Drugs & More

You’ve probably seen the Internet memes. “When 2016 started, I looked like this. [Insert picture of young Leo DiCaprio.] Now I look like this. [Leo, with mountain beard, after mud-wrestling with a grizzly in The Revenant.]” In life science terms, let’s just say all our telomeres feel a lot shorter than 12 months ago. The biggest issues of 2016 are also the biggest questions of 2017: What do the Trump administration and Republican-led Congress have in store for federal health initiatives, ...
Tags: Deals, Congress, Senate, Trends, People, Alzheimer's, Fda, National, Novartis, Leo, Biotech, Microbiome, Roundups, Cystic Fibrosis, Life Sciences, Martin Shkreli


New research sheds light 'gender gap' in cystic fibrosis

A minor hiccup in the sequence of a human gene can have devastating impacts on health.
Tags: Cystic Fibrosis


Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push

Investors hoping to buy into the vast, yet still unproven drugmaking potential of the gene editing system CRISPR-Cas9 will soon have three different companies to choose from. CRISPR Therapeutics filed for an IPO on Friday, meaning it could soon join Boston-area rivals Editas Medicine and Intellia Therapeutics in the expanding club of publicly traded CRISPR-Cas9 drug developers. Basel, Switzerland- and Cambridge, MA-based CRISPR has been slowly amassing rounds of venture funding, adding part...
Tags: Startups, Ipo, Boston, Trends, IPOs, Cambridge, Fda, Novartis, Cystic Fibrosis, Crispr, New Enterprise Associates, Life Sciences, Bayer, Flagship Ventures, Polaris Partners, Editas Medicine


Inhaled-Drug Maker Savara Buys European Biotech With Two Candidates

Austin—Savara Pharmaceuticals, a privately held drug developer with an inhaled formulation of an antibiotic for a type of lung infection, is announcing today that it is acquiring two new drug programs. The Austin, TX-based company also is seeking new funding that could precede an initial public offering. “Now that we have multiple products in the pipeline, we will begin the process of raising a mezzanine round with the eye toward potential IPO,” says Savara’s CEO Rob Neville. In an all-stoc...
Tags: Europe, Japan, Texas, Funding, Trends, Eu, Vc, Venture Capital, Denmark, National Institutes of Health, Fda, Biotech, Pharma, Cystic Fibrosis, Venture Funding, Series B


Medical News Today: Cystic fibrosis patients may benefit from repurposed approved drug

Study finds drug approved to treat metabolic acidosis intravenously might serve as an aerosol to reduce airway surface liquid acidity in cystic fibrosis.
Tags: Cystic Fibrosis


Medical News Today: Cystic fibrosis: New molecule may prolong patient survival

Scientists have discovered a new protease inhibitor with potential to improve airway hydration and mucus clearance, and thus reduce frequency of infection in cystic fibrosis.
Tags: Cystic Fibrosis


Women with cystic fibrosis may benefit from specialized sexual and reproductive health care and education, UPMC study shows

For female cystic fibrosis (CF) patients and providers, individual CF health care specialists have a significant role in helping patients gain access to educational resources that can help them...
Tags: Cystic Fibrosis, UPMC


Tour of Texas: Savara, Brainspace, JLabs, InCube, Trinity University

Happy Monday. Let’s start the week with a recap of the latest innovation news from around Texas, including new funding and support for startups and entrepreneurs, artificial intelligence, and a treatment for cystic fibrosis patients. Austin: —Austin’s Savara Pharmaceuticals has raised $20 million in Series C funding to further develop AeroVanc, what it says is the first inhaled antibiotic for the methicillin-resistant Staphylococcus aureus (MRSA) lung infection in people who have cystic fib...
Tags: Startups, Accelerator, Texas, Entrepreneurship, Funding, Investment, Analytics, People, Artificial Intelligence, Software, Austin, Lung Cancer, Healthcare, Innovation, Venture Capital, Machine Learning


Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

Austin — Fresh off of releasing results from a Phase 2 clinical trial, Savara Pharmaceuticals has announced $20 million in Series C funding that it will use to take its inhaled version of an antibiotic to Phase 3. Savara, based in Austin, TX, plans to begin enrollment in the Phase 3 study at the end of 2016 after it completes the selection of an expected 80 research sites in the U.S. and Canada. The company says it is developing the first inhaled antibiotic for the methicillin-resistant Sta...
Tags: Texas, Funding, Vc, Venture Capital, National Institutes of Health, Biotech, Pharma, Cystic Fibrosis, Venture Funding, Series B, Life Sciences, Mrsa, Austin TX, Cystic Fibrosis Foundation, Texas Emerging Technology Fund, National blog main


East Coast Biotech Roundup: Scangos, CRISPR, Yumanity, Synlogic & More

Biotech and pharma executives from across the country descended on frigid midtown Manhattan this week for the BIO CEO & Investor Conference, and we’ve got a few tidbits from the festivities—as well as the rest of your East Coast headlines—below. But first, a programming note. The East Coast roundup has moved to a weekly Thursday spot, switching places with Alex Lash’s West Coast counterpart, which will now run each Friday—so set your DVRs accordingly. With that, on to the news. — Biogen (NA...
Tags: Deals, New York, Ipo, New York City, America, Infliximab, Remicade, Cambridge, Manhattan, Alzheimer's, Fda, GlaxoSmithKline, Pfizer, Abbvie, West Coast, Biotech


Proteostasis Cuts Price But Heads to Nasdaq After $50M IPO

The stock markets haven’t been kind to biotech companies this year whether the companies are already public or trying to be. Proteostasis Therapeutics, a developer of drugs for cystic fibrosis and other diseases, is the latest example. It had to significantly discount its IPO demands to make it to the Nasdaq. Cambridge, MA-based Proteostasis raised $50 million by selling 6.25 million shares at $8 apiece, well below the company’s projections last week. Proteostasis had been hoping to sell ne...
Tags: Deals, Japan, China, Ipo, Boston, IPOs, Chicago, Fda, Novartis, Seattle, Nasdaq, Cystic Fibrosis, New Enterprise Associates, Life Sciences, Editas Medicine, Elan